Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Phase III confirmatory study of Photrex planned

Feb. 4, 2005

Pharmos receives milestone for Zylet launch

Jan. 26, 2005

Macugen now available

Jan. 25, 2005

Jerini and Alcon collaborate on novel ophthalmology drugs

Jan. 24, 2005

Phase II study evaluates recombinant microplasmin in vitreoretinal disorders

Jan. 21, 2005

Evidence suggests that retinitis pigmentosa may be caused by mutations in the CA4 gene

Jan. 17, 2005

Phase II data on the efficacy of squalamine in wet AMD

Jan. 13, 2005

ISTA launches Vitrase

Jan. 11, 2005

Squalamine selected for CMA Pilot 2 program

Jan. 10, 2005

Macugen approved for neovascular AMD

Dec. 21, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...